Viridian Therapeutics, Inc. VRDN
29.96 USD -1.48 (-4.71%)
Regular-session close
29.96 0.00 0.00%
After hours · Nov 20, 4:38 PM ET
29.87 Day range 31.75
13.18 52-week range 34.29
- YTD
- -3.73%
- 1 year
- +1.66%
Held by funds
131 US ETFs and mutual funds hold VRDN · largest positions
- IWM 0.10% of fund $74.26M
- XBI 0.74% of fund $73.71M
- VTI 0.00% of fund $69.26M
- FBTTX 1.80% of fund $42.38M
- FDSCX 0.43% of fund $31.60M
- NJM 0.04% of fund $31.21M
- FSPHX 0.45% of fund $30.89M
- FIDGX 0.33% of fund $29.39M
- FBIOX 0.45% of fund $26.94M
- VXF 0.03% of fund $26.40M
- IWN 0.17% of fund $24.24M
- FSSNX 0.07% of fund $22.90M
- DFAS 0.06% of fund $20.04M
- VEXRX 0.08% of fund $17.66M
- SCHA 0.08% of fund $17.22M
- FHCIX 0.47% of fund $15.65M
- FNITX 0.05% of fund $13.59M
- VSEQX 0.10% of fund $12.62M
- VTWO 0.07% of fund $12.02M
- FSMAX 0.03% of fund $10.84M
Ownership
Held by insiders 0.17%
Held by institutions 125.03%
Float held by institutions 125.24%
Institutions 324
Top institutional holders
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 15.42% | 17,509,137 | 524.57M | Sep 29, 2026 |
| Blackrock Inc. | 8.22% | 9,329,150 | 279.50M | Sep 29, 2026 |
| Paradigm Biocapital Advisors LP | 7.27% | 8,257,672 | 247.40M | Sep 29, 2026 |
| Bellevue Group AG | 6.26% | 7,109,318 | 213.00M | Sep 29, 2026 |
| Kynam Capital Management, LP | 5.41% | 6,148,000 | 184.19M | Sep 29, 2026 |
| Price (T.Rowe) Associates Inc | 4.51% | 5,123,569 | 153.50M | Sep 29, 2026 |
Top mutual fund holders
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.94% | 3,336,970 | 99.98M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.28% | 2,590,081 | 77.60M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.20% | 2,495,461 | 74.76M | Sep 29, 2026 |
| Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 1.81% | 2,058,130 | 61.66M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 1.32% | 1,500,000 | 44.94M | Sep 29, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 1.27% | 1,447,742 | 43.37M | Jun 29, 2026 |
Included in Plus and up
Sign in to see Institutional ownership
How much funds own from their 13F filings, quarter by quarter, and the largest holders.
Free with an account
Sign in to see Insider activity
Two years of insider buying and selling by month, marked on the price.
Included in Plus and up
Sign in to see Congress trading
Every stock trade disclosed by members of the US Senate and House.
Free with an account
Sign in to see CEO compensation
What the chief executive was paid each year, by salary, bonus and stock, beside the company's earnings.
Free with an account
Sign in to see Board of directors
Who sits on the board, who chairs it, and how long each director has served.
Insiders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BEETHAM THOMAS W | Chief Operating Officer | Conversion of Exercise of derivative security | Mar 2, 2026 | 13,361 |
| FAIRMOUNT FUNDS MANAGEMENT LLC | Beneficial Owner of more than 10% of a Class of Security | Purchase | May 10, 2026 | 0 |
| HARMON SETH | Chief Financial Officer | Conversion of Exercise of derivative security | Mar 2, 2026 | 7,790 |
| MAHONEY STEPHEN F | Chief Executive Officer | Conversion of Exercise of derivative security | Mar 2, 2026 | 33,349 |
| TOUSIGNANT JENNIFER | Officer | Conversion of Exercise of derivative security | Aug 18, 2026 | 0 |
| TRIPURANENI RADHIKA | Officer | Conversion of Exercise of derivative security | Aug 13, 2026 | 40,000 |
